- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 | 2 | GlobeNewswire (USA) | ||
| 13.05. | Orchestra BioMed GAAP EPS of -$0.49, revenue of $0.9M | 1 | Seeking Alpha | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones | 92 | GlobeNewswire (Europe) | FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings... ► Artikel lesen | |
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 12.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure | 2 | GlobeNewswire (USA) | ||
| 29.04. | FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR | 2 | RTTNews | ||
| 29.04. | Orchestra BioMed wins FDA IDE for sirolimus-angioballoon | 1 | MassDevice | ||
| 29.04. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.04. | Orchestra BioMed's Hypertension Device Wins FDA Breakthrough Designation | 1 | MedCity News | ||
| 24.04. | Orchestra BioMed stock holds Buy rating, $12 target from H.C. Wainwright | 1 | Investing.com | ||
| 23.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.04. | Orchestra Biomed wins FDA breakthrough nod for hypertension treatment | 1 | MassDevice | ||
| 22.04. | HotStocks USA: +22 % bei Orchestra BioMed Holdings | 3 | stock3.com | ||
| 22.04. | Pre-market Movers: Gelteq, MicroCloud Hologram, SHF Holdings, Orchestra Biomed, Fulcrum Therapeutics | 859 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green Gelteq Ltd (GELS) is up over 445% at $5.05.
MicroCloud... ► Artikel lesen | |
| 22.04. | Orchestra BioMed-Aktien steigen nach FDA-Breakthrough-Designation | 3 | Investing.com Deutsch | ||
| 22.04. | Orchestra BioMed shares surge on FDA breakthrough designation | 1 | Investing.com | ||
| 22.04. | FDA gewährt Orchestra BioMed's AVIM-Therapie Breakthrough-Status | 1 | Investing.com Deutsch | ||
| 22.04. | FDA grants breakthrough status to Orchestra BioMed's AVIM therapy | 2 | Investing.com | ||
| 22.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy | 747 | GlobeNewswire (Europe) | Breakthrough Device Designation ("BDD") applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular riskBDD also encompasses pacemaker-indicated... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,165 (-5,54 %) liegt der Kurs bei 2,815 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.